Unlock instant, AI-driven research and patent intelligence for your innovation.

IDO1 related vaccine and application thereof

A technology for vaccines and uses, applied in the field of biomedicine

Active Publication Date: 2022-06-24
SHENZHEN GINO BIOTECHNOLOGY CO LTD +1
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the tumor immune environment, regulatory immune cells may suppress the body's immune killing response to malignant cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • IDO1 related vaccine and application thereof
  • IDO1 related vaccine and application thereof
  • IDO1 related vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Immunogenicity prediction of polypeptides

[0051] According to the selected allele typing of HLA-A11:01 and HLA-A24:02, the invention uses the self-developed biological information analysis process to cut the full length of the IDO1 protein into a polypeptide sequence of 8-11 mer amino acids, and the IDO1 gene encodes The length of the protein is 403 amino acids, the molecular weight is 45326 Daltons, and the cleaved polypeptide sequence is 1578. The presentation ability prediction and affinity prediction were performed on these 1578 polypeptides, respectively. The presentation ability score is represented by a numerical value between 0 and 1. The higher the score value, the stronger the presentation ability, and the score greater than 0.1 indicates that the polypeptide has the presentation ability. Affinity score is expressed by IC50 score, IC50 less than 500 indicates that the polypeptide has affinity, and IC50 less than 50 indicates that the polypeptide h...

Embodiment 2

[0056] Example 2 Affinity verification of polypeptide T2

[0057] Take 2×10 5 T2 cells were plated with 500 μL containing human beta 2 Microglobulin (final concentration, 3 μg / ml) in IMDM serum-free medium was resuspended in a 24-well plate, and the peptides listed in Table 1 (final concentration 100 μM) were added. 2 ), cultured overnight. Two replicate wells per group; T2 cells without peptide added were used as background controls. Cells were harvested by centrifugation at 200g for 5 minutes. After the cells were washed twice with PBS, the cells were directly incubated with anti-HLA-A11:01 / HLA-A24:02 FITC monoclonal antibody at 4°C for 30 minutes. Then analyzed by flow cytometer. Fluorescence Index (FI) was calculated with the following formula: FI = [Mean Fluorescence Intensity (MFI) sample - MFI background ] / MFI background , where MFI background Represents values ​​without peptides. FI > 1.5 indicates that the peptide has high affinity for HLA-A11:01 or HLA-A24:0...

Embodiment 3

[0061] Example 3 Mass spectrometry experiments verify that peptides are presented by HLA molecules on the surface of tumor cells

[0062] The present invention enriches the polypeptide-MHC complex on the cell surface by means of co-immunoprecipitation-mass spectrometry combination, and identifies whether the MHC molecule on the tumor cell surface presents the polypeptide. The specific method is as follows:

[0063] 1) Separation and purification of MHC-I-restricted T-cell epitope peptides: use pan-MHC-I A / B / C antibody (clone number: w6 / 32) and sepharose CL-4B beads coupled with protein A molecules on the surface Bind at 4°C for 1 hour, and use NanoDrop to detect the residual antibody content in the supernatant. The antibody binding rate > 90% is considered qualified, and pan-MHC-I A / B / C-binding sepharose is prepared and used at 4°C. Add 40ml of RIPA lysate to SKMEL5 and HCT8 cell samples respectively, incubate at 4°C for 1 hour, centrifuge at 12,000 rpm for 30min, add sepharo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an IDO1 related vaccine and application thereof, the IDO1 related vaccine comprises a separated polypeptide, a separated nucleic acid, an antigen presenting cell, an immune cell and / or an antibody, and the separated polypeptide has an amino acid sequence shown as any one of SEQ ID NO: 2, 3, 5, 6, 8, 9, 11, 13-15, 18-20, 22-24, 26-28, 30 and 32-36 or a functional analogue thereof. The vaccine provided by the invention can take the immunosuppressive protein IDO1 epitope as a target spot, improves the activity and number of anti-tumor immunosuppressive cells in a tumor microenvironment, specifically removes negative regulation cells such as stromal cells and immune cells in the tumor microenvironment and tumor cells expressing IDO1, is high in safety, and has important significance in prevention and treatment of cancers.

Description

technical field [0001] The present invention relates to the field of biomedicine. In particular, the present invention relates to IDO1-related vaccines and applications thereof. Background technique [0002] The immune system contains many types of regulatory immune cells, and their role is to control the strength of the body's immune response and maintain immune balance. Regulatory immune cells mainly include regulatory T cells (Tregs, Regulatory Tcells), M2 macrophages (M2 macrophage), myeloid-derived suppressor cells (MDSCs, myeloid-derived suppressor cells) and different dendritic cells (DCs, dendritic cells) ) subgroup. The immunosuppressive process involving regulatory immune cells is a mechanism that controls the size and duration of specific immune responses. The difference between immunosuppression and immune tolerance is that immune regulation is an active immune activation. Studies have shown that regulatory immune cells can express a variety of immunosuppress...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N9/02C12N15/53C12N5/0784C12N5/0781C12N5/0786C12N5/0783A61K39/00A61P35/00
CPCC12N9/0069C12N5/0639C12N5/0635C12N5/0645C12N5/0636C12Y113/11052A61K39/0011A61P35/00
Inventor 李波李冬丽张乐黄英刘耿
Owner SHENZHEN GINO BIOTECHNOLOGY CO LTD